We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
The current 0UNL market cap is 9B. The company's latest EPS is USD -1.9301 and P/E is -0.24.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.19B | 114.62M | 152.92M | 101.91M | 92.06M |
| Operating Income | 687.93M | -440.04M | -379.92M | -446.1M | -313.73M |
| Net Income | 681.31M | -440.67M | -444.44M | -523.84M | -368.2M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.15B | 1.98B | 1.54B | 1.12B | 710.6M |
| Total Liabilities | 432.6M | 571.97M | 461.47M | 437.68M | 343.96M |
| Total Equity | 1.72B | 1.41B | 1.08B | 679.51M | 366.64M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 718.21M | -328.68M | -313.29M | -412.66M | -304.01M |
| Investing | -1.38B | 206.89M | 496.21M | 202.78M | 365.84M |
| Financing | 851.97M | 23.36M | -80.35M | 36.24M | 1.51M |
| Market Cap | 9B |
| Price to Earnings Ratio | -0.24 |
| Price to Sales Ratio | 0.97 |
| Price to Cash Ratio | 1.02 |
| Price to Book Ratio | 0.24 |
| Dividend Yield | - |
| Shares Outstanding | 190.77M |
| Average Volume (1 week) | 8.05k |
| Average Volume (1 Month) | 13.48k |
| 52 Week Change | 0.0% |
| 52 Week High | 47.18 |
| 52 Week Low | 47.18 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Nektar Therapeutics |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.nektar.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
